Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash & Equivalents (2016 - 2025)

ImmunityBio (IBRX) has disclosed Cash & Equivalents for 13 consecutive years, with $88.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 38.41% to $88.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $88.3 million through Dec 2025, down 38.41% year-over-year, with the annual reading at $88.3 million for FY2025, 38.41% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $88.3 million at ImmunityBio, up from $60.2 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $265.5 million in Q4 2023, with the low at $36.4 million in Q1 2022.
  • Average Cash & Equivalents over 5 years is $106.1 million, with a median of $96.3 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents soared 418.69% in 2021, then tumbled 54.4% in 2025.
  • Over 5 years, Cash & Equivalents stood at $181.1 million in 2021, then tumbled by 42.22% to $104.6 million in 2022, then surged by 153.68% to $265.5 million in 2023, then crashed by 45.97% to $143.4 million in 2024, then crashed by 38.41% to $88.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $88.3 million, $60.2 million, and $137.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.